Exelixis (EXEL) Capital Expenditures Growth (5y) (2015 - 2026)
Powered by 
Analysis
Exelixis (EXEL) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | -19.54% |
| Apr 3, 2026 | -35.54% |
| Jan 2, 2026 | -45.81% |
| Apr 4, 2025 | -0.06% |
| Sep 27, 2024 | 31.83% |
| Jun 28, 2024 | 40.29% |
| Mar 29, 2024 | 33.25% |
| Dec 29, 2023 | 35.33% |
| Sep 29, 2023 | -9.24% |
| Jun 30, 2023 | -7.09% |
| Mar 31, 2023 | 12.72% |
| Dec 30, 2022 | -11.30% |
| Sep 30, 2022 | 34.38% |
| Jul 1, 2022 | 37.48% |
| Apr 1, 2022 | 47.48% |
| Dec 31, 2021 | 58.97% |
| Oct 1, 2021 | 237.72% |
| Jul 2, 2021 | 119.02% |
| Apr 2, 2021 | 81.83% |
| Apr 3, 2020 | 91.49% |